Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

41,479 stories, page 448 of 692

Advanced search

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

GERD affects about 20% of U.S. population as JAQBO nears Phase 3

Stock TitanOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Business WireOriginal source

🌍Jul 23discoverynews.google.comTier 2 · Trade media

Roche Diagnostics growth remains muted amid China headwinds

Fierce BiotechOriginal source

🇩🇪Jul 23Researchuni-heidelberg.deTier 2 · Direct publisher

Restoration of the Botanic Garden: “A Treasure for Research”

Heidelberg UniversityOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Veraxa Biotech names Christoph Erkel as chief scientific officer

Investing.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Is West Pharmaceutical Services Inc (WST) Undervalued After Q2 E

GuruFocusOriginal source

🇨🇦Jul 23Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

OverStitch™ Suture Cinch and Suture Cinch–Long

Boston Scientific is initiating removal of specific lots of OverStitch™ Suture Cinch and Suture Cinc...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 23Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

HeartSine® Samaritan® PAD SAM 350P/SAM 360P/SAM 500P - Membrane Tail

Stryker has recently identified an issue with the membrane tail, an internal component, which could...

Health Canada Recalls and Safety AlertsOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars

The Chronicle-JournalOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data

Investing.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Everything you need to know about clinical trial legislation changes

The Pharmaceutical JournalOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)

Seeking AlphaOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Form 8-K WEST PHARMACEUTICAL SERV For: Jul 23

StreetInsiderOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates

Yahoo FinanceOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer

Quiver QuantitativeOriginal source

🇺🇰Jul 23Regulatorygov.ukTier 1 · Regulatory source

Rabies post exposure risk assessment form and calendar

Risk assessment form for rabies post exposure treatment.

UK Health Security AgencyOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

When Compounding Goes Bad, People Pay the Price

RealClearHealthOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

SARTORIUS STEDIM BIOTECH : Buy rating from RBC

marketscreener.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of Hyundai Pharmaceutical Co., Ltd. – KRX:004310

TradingViewOriginal source

🌍Jul 23Industryamarin.co.thTier 3 · Secondary coverage

Amarin Group ร่วมกับชุมชน จัดกิจกรรมบริจาคโลหิต ครั้งที่ 2/2569

Amarin CorporationOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares

Stock TitanOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch

Kalkine MediaOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma Plans Global Phase 3 Trial for About 111 Patients

Stock TitanOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

PR NewswireOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Eli Lilly’s Next-Gen Obesity Drug Clears Phase 3 Trials, But Heart Benefits Remain Unproven

streamlinefeed.co.keOriginal source

🇺🇸Jul 23Industryinvestor.lilly.comTier 1 · Company source

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Eli Lilly NewsOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components

marketscreener.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Initiate Prioritizes Early-Stage Biotech Startups With Proprietary Data Over AI Models

geneonline.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBIT forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513

TradingViewOriginal source

🌍Jul 23discoverynews.google.comTier 2 · Trade media

Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near

Endpoints NewsOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Gibson Dunn guides biotech reverse merger

ICLGOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

(WST) West Pharmaceutical Services, Inc. Expects Q3 Revenue Range $820.0M - $835.0M

marketscreener.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

(WST) West Pharmaceutical Services Expects Full Year 2026 Adjusted EPS Range $8.85 - $9.05, vs. FactSet Est of $8.62

marketscreener.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Earnings Flash (WST) West Pharmaceutical Services, Inc. Reports Q2 Revenue $872.3M, vs. FactSet Est of $840.0M

marketscreener.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Earnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $2.08

marketscreener.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Militia Capital Management LLC Takes $3.50 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services earnings beat by $0.29, revenue topped estimates

Investing.com South AfricaOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

US intensifies pressure on Germany over pharmaceutical pricing policies

HariciOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Q2 sales beats on biologics, HPV growth; raises outlook

TradingViewOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services earnings beat by $0.29, revenue topped estimates

Investing.comOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Kolon TissueGene CEO Jeon Seung-ho: “TG-C clinical trial was not a failure…official report due in Q4”

더바이오Original source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical: Q2 Earnings Snapshot

WKYCOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical company warns that a single cigarette butt contaminates a thousand liters of water

Plataforma MediaOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

BRIEF-West Pharmaceutical Q2 Adjusted EPS USD 2.37 Vs. IBES Estimate USD 2.08

TradingViewOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Agricultural biotech firm Moa Technology raises £22.2m

UKTNOriginal source

🇺🇰Jul 23Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial

PubMed Lancet RSSOriginal source

🇺🇸Jul 23Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Reply to: Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603

PubMed Journal of Clinical Oncology RSSOriginal source

🇺🇸Jul 23Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

PubMed Journal of Clinical Oncology RSSOriginal source

🇺🇸Jul 23Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Into the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapies

PubMed Journal of Clinical Oncology RSSOriginal source

🇺🇸Jul 23Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603

PubMed Journal of Clinical Oncology RSSOriginal source

🇺🇸Jul 23Researchnews.nm.orgTier 2 · Direct publisher

Allergic to general anesthesia, Wisconsin mom receives life-saving kidney transplant while fully awake

Northwestern MedicineOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Cheiron lands $8 million seed for AI-driven development platform

The Pharma LetterOriginal source

🇺🇰Jul 23Regulatorygov.ukTier 1 · Regulatory source

Adult social care client level data, England: quarterly update to September 2025

Official statistics in development on insights from client level data from local authorities, includ...

UK Department of Health and Social CareOriginal source

🇺🇰Jul 23Regulatorygov.ukTier 1 · Regulatory source

Adult social care client level data, England: quarterly update to December 2025

Official statistics in development on insights from client level data from local authorities, includ...

UK Department of Health and Social CareOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Etcamah clears Europe with US verdict on breast cancer switch pending

The Pharma LetterOriginal source

🌍Jul 23discoverynews.google.comTier 2 · Trade media

Pharmaceutical Technology

Pharmaceutical TechnologyOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Toni Daa Dhaba, 11 others face FDA action over hygiene lapses

The Indian ExpressOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

Lundbeck receives FDA advantage for new sleep drug candidate

medwatch.comOriginal source

🌍Jul 23discoverynews.google.comTier 2 · Trade media

‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins

Fierce BiotechOriginal source

🌍Jul 23discoverynews.google.comTier 3 · Aggregated media

FDA panel considers easing peptide restrictions

WXXI NewsOriginal source

Pharmaceutical industry news

GERD affects about 20% of U.S. population as JAQBO nears Phase 3

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Roche Diagnostics growth remains muted amid China headwinds

Restoration of the Botanic Garden: “A Treasure for Research”

Veraxa Biotech names Christoph Erkel as chief scientific officer

Is West Pharmaceutical Services Inc (WST) Undervalued After Q2 E

OverStitch™ Suture Cinch and Suture Cinch–Long

HeartSine® Samaritan® PAD SAM 350P/SAM 360P/SAM 500P - Membrane Tail

West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars

H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data

Everything you need to know about clinical trial legislation changes

Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)

Form 8-K WEST PHARMACEUTICAL SERV For: Jul 23

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates

VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer

Rabies post exposure risk assessment form and calendar

When Compounding Goes Bad, People Pay the Price

SARTORIUS STEDIM BIOTECH : Buy rating from RBC

Price to sales forward of Hyundai Pharmaceutical Co., Ltd. – KRX:004310

Amarin Group ร่วมกับชุมชน จัดกิจกรรมบริจาคโลหิต ครั้งที่ 2/2569

OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares

OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch

OKYO Pharma Plans Global Phase 3 Trial for About 111 Patients

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Eli Lilly’s Next-Gen Obesity Drug Clears Phase 3 Trials, But Heart Benefits Remain Unproven

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components

Initiate Prioritizes Early-Stage Biotech Startups With Proprietary Data Over AI Models

Enterprise value to EBIT forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513

Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near

Gibson Dunn guides biotech reverse merger

(WST) West Pharmaceutical Services, Inc. Expects Q3 Revenue Range $820.0M - $835.0M

(WST) West Pharmaceutical Services Expects Full Year 2026 Adjusted EPS Range $8.85 - $9.05, vs. FactSet Est of $8.62

Earnings Flash (WST) West Pharmaceutical Services, Inc. Reports Q2 Revenue $872.3M, vs. FactSet Est of $840.0M

Earnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $2.08

Militia Capital Management LLC Takes $3.50 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

West Pharmaceutical Services earnings beat by $0.29, revenue topped estimates

US intensifies pressure on Germany over pharmaceutical pricing policies

West Pharmaceutical Q2 sales beats on biologics, HPV growth; raises outlook

West Pharmaceutical Services earnings beat by $0.29, revenue topped estimates

﻿﻿Kolon TissueGene CEO Jeon Seung-ho: “TG-C clinical trial was not a failure…official report due in Q4”

West Pharmaceutical: Q2 Earnings Snapshot

Pharmaceutical company warns that a single cigarette butt contaminates a thousand liters of water

BRIEF-West Pharmaceutical Q2 Adjusted EPS USD 2.37 Vs. IBES Estimate USD 2.08

Agricultural biotech firm Moa Technology raises £22.2m

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial

Reply to: Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

Into the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapies

Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603

Allergic to general anesthesia, Wisconsin mom receives life-saving kidney transplant while fully awake

Cheiron lands $8 million seed for AI-driven development platform

Adult social care client level data, England: quarterly update to September 2025

Adult social care client level data, England: quarterly update to December 2025

Etcamah clears Europe with US verdict on breast cancer switch pending

Pharmaceutical Technology

Toni Daa Dhaba, 11 others face FDA action over hygiene lapses

Lundbeck receives FDA advantage for new sleep drug candidate

‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins

FDA panel considers easing peptide restrictions

Kolon TissueGene CEO Jeon Seung-ho: “TG-C clinical trial was not a failure…official report due in Q4”